D-PHARM ANNOUNCES INTERIM STUDY RESULTS OF DP-B99 IN ACUTE STROKE PATIENTS

D-Pharm has announced interim results from the ongoing Phase II study of its neuroprotective agent DP-b99 in acute stroke patients. DP-b99 addresses the array of damaging processes occurring in the brains of stroke patients.

DP-b99 is administered intravenously over four days, with the first administration up to nine hours following stroke onset. The patient group is stratified into those treated within six hours and within nine hours following stroke onset.

The interim analysis trial data was blinded, and the patients were split into groups A or B without disclosure of active drug or placebo designation. Thirty-one subjects were in each group. Both groups were comparable for most baseline characteristics, including gender, age, body mass index and mean NIH Stroke Scale score. The rate, nature and distribution of adverse events were similar in both groups.